Neoadjuvant Therapy for Locally Advanced Colon Cancer
To determine the Efficacy and Safety of camrelizumab and apatinib combined with chemotherapy (mFOLFOX6) for MSS/pMMR locally advanced colon cancer.
Colon Cancer|Neoadjuvant Therapy
DRUG: Camrelizumab , apatinib and chemotherapy
Tumor regression rate of MSS/pMMR patients, Tumor regression rate (TRG) was evaluated by pathologist, using Dworak criteria. The percentage of TRG 2,3,4 to all person will be evaluated at time of radical resection of colon cancer following neoadjuvant treatment. Grade 0: no regression, Grade 1: dominant tumor mass with obvious fibrosis and/or vasculopathy; Grade 2: dominantly fibrotic changes with few tumor cells or groups (easy to find); Grade 3: very few (difficult to find microscopically) tumor cells in fibrotic tissue with or without mucous substance; Grade 4: no tumor cells, only fibrotic mass (total regression or response), 3 months
pathologic complete response (pCR) rates, Percentage of patients with pathological complete response assessed based on Dworak criteria, 3 months|R0 resection rate, R0 resection accounted for the percentage of all surgical patients, 2 years|The rate of 2 year Disease free survival (DFS), Disease-free survival (DFS) is defined as the time from operation to recurrence of tumor or death. We will evaluate 2 year DFS., 2 years|overall survival (OS), Refers to the time of death from enrollment to any cause, 2 years|event free survival (EFS), The period from the beginning of neoadjuvant therapy to the occurrence of any of the following events, whichever occurs first: tumor progression as assessed by RECIST 1.1; Tumor recurrence, including local recurrence or distant metastasis; Death from any cause;, 2 years|perioperative complication rate, The complication rate of all patients during the period around the time of a surgical operation, 3 months|mortality rate, the ratio between deaths and all patients in the study during treatment, 6 months
To determine the rate of tumor regression grade 2-4 at time of radical resection of MSS/pMMR colon cancer following neoadjuvant treatment.To determine the pathologic downstage rates at time of radical resection of colon cancer following neoadjuvant treatment, pathologic complete response (pCR) rates, R0 resection rate, 2 year Disease free survival, OS(overall survival) and adverse events, including perioperative complication and mortality rate.

To determine the pathologic downstage rates and pCR rate of radical resection of MSI/dMMR colon cancer.